Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have received a confirmed diagnosis that includes pathology results and molecular subtype information
- People who are able and willing to sign a written consent form
Who may not be able to join:
For the cancer group:
- People who have had, or currently have, another type of cancer
- People who are pregnant or planning to become pregnant
- People who have already received any cancer treatment (such as surgery, chemotherapy, radiation, targeted therapy, or immunotherapy) before their blood sample is taken
- People who have had a blood transfusion in the past month
- People who have previously received a donated organ or donated stem cells from another person
- People who have had a persistent fever or have been taking anti-inflammatory medication in the 14 days before their blood sample is taken
- People whose physical condition makes a blood draw unsuitable
- People who are unable to give consent or who do not wish to have a blood draw taken
- People with any other condition that the research team considers may make participation unsuitable or interfere with the study (confirm with trial site)
For the non-cancerous (benign) disease group:
- People with a past or current history of any cancer
- People with any current precancerous conditions
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Establish DNA methylation profiles of two populations by collecting tissues and peripheral blood related to benign and malignant breast nodules.; Based on DNA methylation profiles, systematically evaluate the signal, noise, and complementarity of methylation biomarkers and ultimately form a set of diagnostic biomarker combinations for breast malignant nodules.; Further develop a methylation assisted diagnostic model that can effectively distinguish between benign and malignant breast nodules.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.